NasdaqGS - Nasdaq Real Time Price USD

Acumen Pharmaceuticals, Inc. (ABOS)

1.0200
-0.0100
(-0.97%)
At close: May 23 at 4:00:01 PM EDT
1.0300
+0.01
+(0.98%)
After hours: May 23 at 6:41:20 PM EDT
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Total Revenue
0
0
0
0
0
Operating Expense
126,613
114,017
61,138
45,237
19,584
Operating Income
-126,613
-114,017
-61,138
-45,237
-19,584
Net Non Operating Interest Income Expense
8,692
10,249
10,210
2,392
84
Other Income Expense
1,669
1,439
-1,443
-11
-81,106
Pretax Income
-116,252
-102,329
-52,371
-42,856
-100,606
Net Income Common Stockholders
-116,252
-102,329
-52,371
-42,856
-100,606
Diluted NI Available to Com Stockholders
-116,252
-102,329
-52,371
-42,856
-100,606
Basic EPS
-1.94
-1.71
-1.08
-1.06
-5.02
Diluted EPS
-1.94
-1.71
-1.08
-1.06
-5.02
Basic Average Shares
60,191.6840
60,013.2770
48,609.3830
40,601.9360
20,057.5340
Diluted Average Shares
60,191.6840
60,013.2770
48,609.3830
40,601.9360
20,057.5340
Total Operating Income as Reported
-126,613
-114,017
-61,138
-45,237
-19,584
Total Expenses
126,613
114,017
61,138
45,237
19,584
Net Income from Continuing & Discontinued Operation
-116,252
-102,329
-52,371
-42,856
-100,606
Normalized Income
-118,082
-103,919
-51,011
-42,856
-19,449
Interest Income
12,783
14,317
10,791
2,392
84
Interest Expense
4,091
4,068
581
0
--
Net Interest Income
8,692
10,249
10,210
2,392
84
EBIT
-112,161
-98,261
-51,790
-42,856
-19,584
EBITDA
-111,982
-98,083
-51,606
-42,687
-19,580
Reconciled Depreciation
179
178
184
169
4
Net Income from Continuing Operation Net Minority Interest
-116,252
-102,329
-52,371
-42,856
-100,606
Total Unusual Items Excluding Goodwill
1,830
1,590
-1,360
--
-81,157
Total Unusual Items
1,830
1,590
-1,360
--
-81,157
Normalized EBITDA
-113,812
-99,673
-50,246
-42,687
61,577
Tax Rate for Calcs
0
0
0
0
0
Tax Effect of Unusual Items
0
0
0
0
0
12/31/2021 - 7/1/2021

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

ARTV Artiva Biotherapeutics, Inc.
1.9500
-1.52%
 
ELDN Eledon Pharmaceuticals, Inc.
3.0500
+0.99%
 
ANTX AN2 Therapeutics, Inc.
1.1700
-1.68%
 
LVTX LAVA Therapeutics N.V.
1.2800
+0.79%
 
CLYM Climb Bio, Inc.
1.1800
-1.67%
 
NKTX Nkarta, Inc.
1.7500
-0.85%
 
SLGL Sol-Gel Technologies Ltd.
7.59
+1.20%
 
ERAS Erasca, Inc.
1.2200
+0.83%
 
PHGE BiomX Inc.
0.5186
-1.97%
 
PLRX Pliant Therapeutics, Inc.
1.2900
-3.73%